logo_ProQR-150x150.png
ProQR Announces Highlights from Analyst Event
November 18, 2021 16:01 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
March 24, 2021 07:00 ET | ProQR Therapeutics N.V.
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)QR-421a observed to be well...
logo_ProQR-150x150.png
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
March 17, 2021 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
February 16, 2021 16:30 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Third Quarter 2020 Operating and Financial Results
November 16, 2020 07:00 ET | ProQR Therapeutics N.V.
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021Enrollment completed for QR-421a...
logo_ProQR-150x150.png
ProQR Announces Second Quarter 2020 Operating and Financial Results
August 06, 2020 16:30 ET | ProQR Therapeutics N.V.
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;Strategic...
logo_ProQR-150x150.png
ProQR Announces Expert Perspectives Conference Call Series
June 12, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
logo_ProQR-150x150.png
ProQR Announces First Quarter 2020 Operating and Financial Results
May 07, 2020 07:00 ET | ProQR Therapeutics N.V.
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation...
logo_ProQR-150x150.png
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
March 31, 2020 06:00 ET | ProQR Therapeutics N.V.
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse...
logo_ProQR-150x150.png
ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
March 25, 2020 16:15 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...